BMC Cancer · 2014 · 23 citations · 22 references
Life SciencesOncologyPharmacologyApoptosisCell SignalingGene ExpressionCancer BiomarkersCancer Cell SignalingCancer MetabolismCancer TranscriptomicsOncogenic Signaling PathwaysAnticancer ActivityAnticancer ChemotherapyCopper SignalingHeat Shock Protein GenesHeat Shock Protein RegulationIntracellular Signaling PathwaysMetal-binding ProteinsOxidative Stress Injury
BACKGROUND: The 90-kDa heat shock protein HSP90AA1 is critical for the stability of several proteins that are important for tumor progression and thus, is a promising target for cancer therapy. Selenosemicarbazone metal complexes have been shown to possess anticancer activity through an unknown molecular mechanism. METHODS: The MTT assay, fluorescence-activated cell sorting, and fluorescent microscopy were used to analyze the mechanism of the anti-cancer activity of the selenosemicarbazone metal complexes. Additionally, RNA-seq was applied to identify transcriptional gene changes, and in turn, the signaling pathways involved in the process of 2-24a/Cu-induced cell death. Last, the expression of HSP90AA1, HSPA1A, PIM1, and AKT proteins in 2-24a/Cu-treated cells were investigated by western blot analysis. RESULTS: A novel selenosemicarbazone copper complex (2-24a/Cu) efficiently induced G2/M arrest and was cytotoxic in cancer cells. 2-24a/Cu significantly induced oxidative stress in cancer cells. Interestingly, although RNA-seq revealed that the transcription of HSP90AA1 was increased in 2-24a/Cu-treated cells, western blotting showed that the expression of HSP90AA1 protein was significantly decreased in these cells. Furthermore, down-regulation of HSP90AA1 led to the degradation of its client proteins (PIM1 and AKT1), which are also cancer therapy targets. CONCLUSION: Our results showed that 2-24a/Cu efficiently generates oxidative stress and down-regulates HSP90AA1 and its client proteins (PIM1, AKT1) in U2os and HeLa cells. These results demonstrate the potential application of this novel copper complex in cancer therapy.
22
PI3K/AKT/mTOR Pathway in Angiogenesis
Jayashree Karar, Amit Maity · Frontiers in Molecular Neuroscience · 2011 · 1.5K citations · Full text
Hsp90 Molecular Chaperone Inhibitors: Are We There Yet?
Clinical Cancer Research · 2012 · 903 citations · Full text
Medicine, Oncology, Pharmacology +16
Danuta S. Kalinowski, Yu Yu, Philip C. Sharpe et al. · Journal of Medicinal Chemistry · 2007 · 221 citations
Yutaka Okawa, Teru Hideshima, Paul M. Steed et al. · Blood · 2008 · 209 citations · Full text
Medicine, Oncology, Pharmacology +16